Literature DB >> 1516489

Maintenance of sulfonylurea responsiveness in NIDDM. Randomized double-blind study of intermittent glyburide therapy.

G Grunberger1.   

Abstract

OBJECTIVE: To assess the effectiveness of intermittent administration of sulfonylurea (glyburide) to patients with non-insulin-dependent diabetes mellitus (NIDDM). RESEARCH DESIGN AND METHODS: A randomized, double-blind, prospective trial compared daily administration with intermittent administration of glyburide to patients who initially responded to the drug. Twenty-eight of 60 patients with NIDDM achieved the predetermined improvement in plasma glucose concentration on glyburide therapy. These 28 responders were enrolled into a 16-wk trial of daily versus intermittent (2 wk on, 2 wk off) glyburide treatment. Laboratory assessment of glycemic control and insulin secretion in fasting and 2-h postprandial states was done every 2 wk.
RESULTS: Patients on continuous glyburide therapy maintained their glycemic control throughout the study. In contrast, patients on the intermittent schedule lost their glycemic control immediately after being placed on placebo. Despite a significant response to each sulfonylurea pulse, these subjects never regained their baseline glycemic levels. Their fructosamine and HbA1c concentrations deteriorated and remained significantly higher than those of the continuously treated subjects.
CONCLUSIONS: Results suggest that administration of glyburide on an intermittent basis after a 2-wk drug-free period to patients initially rendered responsive to sulfonylurea therapy is without clinical merit.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516489     DOI: 10.2337/diacare.15.5.696

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  2 in total

Review 1.  Continuous versus intermittent sulphonylurea therapy in non-insulin-dependent diabetes mellitus.

Authors:  G Grunberger
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

2.  Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea.

Authors:  Tada Kunavisarut; Sutin Sriussadaporn; Raweewan Lertwattanarak
Journal:  Diabetes Metab Syndr Obes       Date:  2019-05-21       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.